896101-79-4

Basic information

• Product Name: TERT-BUTYL 3-(CYANOMETHYL)-5-METHOXY-1H-INDOLE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 3-(CYANOMETHYL)-5-METHOXY-1H-INDOLE-1-CARBOXYLATE
• CAS NO: 896101-79-4
• Molecular Formula: C16H18N2O3
• Molecular Weight: 286.32572
• Mol File: 896101-79-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: TERT-BUTYL 3-(CYANOMETHYL)-5-METHOXY-1H-INDOLE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-(CYANOMETHYL)-5-METHOXY-1H-INDOLE-1-CARBOXYLATE(896101-79-4)
• EPA Substance Registry System: TERT-BUTYL 3-(CYANOMETHYL)-5-METHOXY-1H-INDOLE-1-CARBOXYLATE(896101-79-4)

Safety Data

• Hazardous Substances Data: 896101-79-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 3-(CYANOMETHYL)-5-METHOXY-1H-INDOLE-1-CARBOXYLATE is used as a key intermediate in the synthesis of drugs and biologically active molecules for various therapeutic applications. Its unique structure allows it to be a versatile component in the development of new pharmaceuticals, contributing to the advancement of medicine and healthcare.
As with any chemical compound, TERT-BUTYL 3-(CYANOMETHYL)-5-METHOXY-1H-INDOLE-1-CARBOXYLATE should be handled with care, adhering to established safety protocols to ensure the well-being of those involved in its production, use, and research.

Upstream product

• 10601-19-1 5-methoxyindole-3-carboxaldehyde 
• 2436-17-1 5-methoxyindole-3-acetonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 190182-60-6 diethyl-(5-methoxy-1H-indol-3-ylmethyl)-amine 
• 1006-94-6 5-methoxylindole 

Downstream Products

• 20731-70-8 5-methoxy-α-methyltryptamine 
• 907602-77-1 tert-butyl-3-(2-cyanopropan-2-yl)-5-methoxy-1H-indole-1-carboxylate 

Relevant articles and documents

Substituted heteroaryl compounds and compositions and uses thereof

The present invention relates to a novel heteroaromatic compound, and a pharmaceutical composition containing the compound. The heteroaromatic compound or pharmaceutical composition containing the compound can be used for exciting a melatonin receptor. The present invention also relates to a preparation method of the compound and pharmaceutical composition thereof, and application of the compound and pharmaceutical composition in treating central nervous system dysfunction of mammals especially human.

Indole derivatives and their application on the medicament

The invention provides a series of indole derivatives or stereoisomers, tautomers, nitrogen oxides, metabolic products and pharmaceutically acceptable salts or prodrugs thereof. The indole derivatives can be taken as melatonin receptor stimulants. The invention also discloses a pharmaceutical composition containing the compounds, and a use of the compounds or the pharmaceutical composition of the compounds in treating the functional disorder of the central nervous system of mammal and in particular human.

Use of derivatives of indoles for the treatment of cancer

The present invention relates to the use of derivatives of indoles having a general formula (I) as follow: for the manufacture of a pharmaceutical composition intended for the treatment of cancer.

Use of derivatives of indoles for the treatment of cancer

The present invention relates to the use of derivatives of indoles having a general formula (I) as follow: for the manufacture of a pharmaceutical composition intended for the treatment of cancer.

The discovery of carboline analogs as potent MAPKAP-K2 inhibitors

The discovery of a series of potent, carboline-based MK2 inhibitors is described. These compounds inhibit MK2 with IC50s as low as 10 nM, as measured in a DELFIA assay. An X-ray crystal structure reveals that they bind in a region near the p-lo

Mapping the melatonin receptor. 7. Subtype selective ligands based on β-substituted N-acyl-5-methoxytryptamines and β-Substituted N-acyl-5-methoxy-1-methyltryptamines

A series of β-substituted and β,β-disubstituted N-acyl 5-methoxy-1-methyltryptamines and 5-methoxytryptamines have been prepared as melatonin analogues to investigate the nature of the binding site of the melatonin receptor. The affinity of analogues was determined in a radioligand binding assay using cloned human MT1 and MT2 receptor subtypes expressed in NIH 3T3 cells. Agonist and antagonist potency of all analogues was measured using the pigment aggregation response of a clonal line of Xenopus laevis melanophores, β-Methylmelatonin (17a) and β,β-dimethylmelatonin (17b), though showing a slight decrease in binding at human receptors, show an increase in potency on Xenopus, N-Butanoyl 5-methoxy-1-methyl-β,β-trimethylenetryptamine (12c) is an antagonist at human MT1 receptors but an agonist at MT2, while N-butanoyl 5-methoxy-1-methyl-β,β-tetramethylenetryptamine (13c) is an antagonist at MT1 but had no action at MT2 and is one of the first examples of an MT1 selective antagonist.